NOW Is the Time for Hepatitis C Virus Elimination
Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.
Communities as Actors in the Research and Development Process
This publication explores the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project.
HCV Elimination Among People Living with and at Risk of HIV: Challenges and Opportunities
Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best practices and challenges for HCV elimination with a specific focus on high-burden populations.
TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus
Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.
Why Hepatitis C Virus Care Remains Inaccessible
This policy brief explores barriers such as the high-burden among marginalized communities, the complicated diagnostic process, and the difficulties of finding the missing millions of people with HCV in most high-burden countries.
2022 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies
On November 16, 2022, please join TAG, INPUD and AfroCAB for our webinar “Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies” at 8:00 a.m. EST / 02:00 p.m. CET / 05:30 IST.
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
LAT CAB Video Presentation
This video, offered here in English, French, and Spanish, was made to be shown at the AfroCAB booth at the 24th International AIDS Conference.
Joint Statement from Leading HIV/AIDS and Viral Hepatitis Advocates regarding Manufacturer Action on the 340B Drug Pricing Program
A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program: